Risk of rehospitalization due to infection among hospitalized patients with : a cohort study.

Background: Reducing rehospitalization has been a primary focus of hospitals and payors. Recurrence of infection (CDI) is common and often results in rehospitalization. Factors that influence rehospitalization for CDI are not well understood.

A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for Recurrent Infection.

infection (CDI) is an intestinal infection that causes morbidity and mortality and places significant burden and cost on the healthcare system, especially in recurrent cases. Antibiotic overuse is well recognized as the leading cause of CDI in high-risk patients, and studies have demonstrated that even short-term antibiotic exposure can cause a large and persistent disturbance to human colonic microbiota. The recovery and sustainability of the gut microbiome after dysbiosis have been associated with fewer CDI recurrences.

Management and Outcomes of Patients at a Specialty Clinic for Infection.

Vancomycin and fidaxomicin taper regimens were the most common treatment strategies employed but nearly half of patients (40/83) referred to our infection (CDI) clinic did not require further treatment. The overall 60-day CDI recurrence rate was 16.9% (11/65).

A review of fecal microbiota, live-jslm for the prevention of recurrent Clostridioides difficile infection.

Purpose: To review the composition, preparation, proposed mechanism of action, safety, efficacy, and current place in therapy of Rebyota (fecal microbiota, live-jslm).

Summary: As the first agent in a new class of drugs, live biotherapeutic products (LBPs), fecal microbiota, live-jslm offers another therapeutic approach for the prevention of recurrent Clostridioides difficile infection (rCDI). LBPs are given following antibiotic therapy for C.

Commonly Reported Mosquito-Borne Viruses in the United States: A Primer for Pharmacists.

Mosquito-borne diseases are a public health concern. Pharmacists are often a patient's first stop for health information and may be asked questions regarding transmission, symptoms, and treatment of mosquito borne viruses (MBVs). The objective of this paper is to review transmission, geographic location, symptoms, diagnosis and treatment of MBVs.